Nutra Pharma Corporation Revenue
Biotechnology Research • 
Boca Raton, Florida, United States • 21-50 Employees
Nutra Pharma Corporation revenue & valuation
| Annual revenue | $163,187 |
| Revenue per employee | $6,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $522,198 |
| Total funding | No funding |
Key Contacts at Nutra Pharma Corporation
Keith Gordon
Veterinary Medical Director Consultant
Joanna Ross
Director Of Operations
Company overview
| Headquarters | 6400 Park of Commerce Blvd, Suite 1B, Boca Raton, Florida 33487, US |
| Phone number | +18778955647 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Rheumatoid Arthritis, Hiv/Aids, Chronic Pain, Pain, Multiple Sclerosis |
| Founded | 2000 |
| Employees | 21-50 |
| Socials |
Nutra Pharma Corporation Email Formats
Nutra Pharma Corporation uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@nutrapharma.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@nutrapharma.com | 100% |
About Nutra Pharma Corporation
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. See: www.nyloxin.com Nutra Pharma also offers Pet Pain-Away: a product aimed at treating moderate to severe chronic pain in companion animals. Pet Pain-Away is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. In addition to the Company's OTC products, Nutra pharma is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. In 2015, the company was granted Orphan Designation for it's drug, RPI-78M for the treatment of pediatric Multiple Sclerosis. Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates and joint venture partners.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Nutra Pharma Corporation has 11 employees across 6 departments.
Departments
Number of employees
Funding Data
Nutra Pharma Corporation has never raised funding before.
Nutra Pharma Corporation Tech Stack
Discover the technologies and tools that power Nutra Pharma Corporation's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Issue trackers
Blogs
Miscellaneous
Security
Miscellaneous
JavaScript frameworks
IaaS
CDN
Miscellaneous
Performance
Netherlands
Germany
CanadaFrequently asked questions
4.8
40,000 users
